Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 22
Filtrar
1.
J Mass Spectrom Adv Clin Lab ; 32: 60-67, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38708432

RESUMO

Introduction: Chromatographic methods for analysis of propofol and its metabolites have been widely used in pharmacokinetic studies of propofol distribution, metabolism, and clearance. Application of chromatographic methods is also needed in clinical and forensic laboratories for detecting and monitoring propofol misuse. Objective: We report a method for sensitive analysis of propofol, propofol 1-glucuronide (PG), 4-hydroxypropofol 1-glucuronide (1-QG), 4-hydroxypropofol 4-glucuronide (4-QG) and 4-hydroxypropofol 4-sulfate (4-QS) in urine by LC-MS/MS analysis. The method employs a simple dilute-and-analyze sample preparation with stable isotope internal standardization. Results: Validation studies demonstrate a linear calibration model (100-10,000 ng/mL), with dilution integrity verified for the extended range of concentrations experienced in propofol use. Criteria-based validation was achieved, including an average coefficient of variation of 6.5 % and a percent bias of -4.2 ng/mL. The method was evaluated in 12 surgical patients, with monitoring periods lasting up to 30 days following intravenous propofol administrations of 100-3000 mg on the day of surgery. While the concentration ratio of PG to 4-hydroxy propofol metabolite decreased significantly in the days following surgery, PG maintained the highest concentration in all specimens. Both PG and 1-QG were detectable throughout the monitoring periods, including in a patient monitored for 30 days. Lower concentrations were determined for 4-QG and 4-QS, with evidence of detection up to 20 days. Propofol was not detectable in any urine specimens, thereby proving ineffective for identifying drug use. Conclusion: The validated method for quantifying propofol metabolites demonstrates its applicability for the sensitive detection of propofol misuse over a long window of drug-use detection.

2.
J Anal Toxicol ; 47(8): 709-718, 2023 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-37540526

RESUMO

Confirmation of cannabinoid use by forensic toxicology testing in urine has been traditionally focused on ∆9-tetrahydrocannabinol (∆9-THC) with analysis of its major metabolite, 11-nor-9-carboxy-∆9-THC (∆9-cTHC), in free and conjugated forms. Legalization of hemp, however, has led to the widespread production and sale of cannabidiol (CBD) derivatives with psycho-activity, including ∆8-THC and ∆10-THC isomers. The increasing availability and growing use of isomer derivatives necessitate an expanded scope of cannabinoid confirmation test protocols. We report a quantitative, isomer-selective method of cannabinoid confirmation by liquid chromatography-tandem mass spectrometry determination of parent drug isomers (∆8-THC, ∆9-THC, ∆10-THC and CBD) as well as isomeric metabolites (∆8-cTHC and ∆9-cTHC). An efficient C18 phase chromatography on 1.6-µm solid core particles was used with a step gradient for near isocratic separation of both early-eluting THC metabolite isomers and later-eluting CBD and THC isomers. A rapid method of hydrolysis, dilution and analysis was employed for the quantitative co-determination of free and conjugated analytes, using stable isotope internal standardization. Method validation is reported, along with interference assessment from a prior confirmation method. Casework experience with the isomer-selective method revealed a 14% prevalence of ∆8-cTHC positive cases with a pattern of concomitant ∆8-THC and ∆9-THC use. A comparison of ∆8-cTHC and ∆9-cTHC phase two metabolism is also reported.


Assuntos
Canabidiol , Canabinoides , Canabinoides/análise , Espectrometria de Massas em Tandem/métodos , Cromatografia Líquida/métodos , Toxicologia Forense , Canabidiol/análise , Dronabinol/análise
3.
Curr Protoc ; 3(1): e644, 2023 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-36622836

RESUMO

Accurate identification and quantification of drugs and their metabolites (analytes) in biological matrices is an analytical foundation of clinical and forensic toxicology. For decades, liquid chromatography interfaced by electrospray ionization with tandem mass spectrometry (LC-ESI-MS/MS) has been a widely used technology for analysis in the field of toxicology, as well as in many other fields of bioscience. It is also known that ion response in LC-ESI-MS/MS analysis is influenced by coeluting biological compounds and that preanalytical sample clean-up is often insufficient in removing these interferences. As a result, a normalization technique is commonly used for assessment and compensation of matrix effects encountered in routine analysis. Internal standardization with a stable isotope analog of the analyte is the predominant normalization technique used in LC-ESI-MS/MS analysis. The technique, however, requires commercial availability or costly custom synthesis of an isotopic analog specific for each analyte. Here we describe an alternative technique for matrix normalization for use in high-volume, multianalyte testing without the need for isotope analogs. The technique involves analysis of the original sample (neat analysis) followed by analysis of a second sample aliquot (spike analysis) that has been fortified with a controlled amount of reference analyte. A calibration procedure similar to internal standardization is employed, using an ion response ratio of neat to fortified analyte. As a demonstration of the technique in multianalyte testing, we provide a detailed protocol for simultaneous detection and quantification of 102 drugs and drug metabolites in human urine. We also provide a support protocol for addition of new analytes to the multianalyte panel, allowing convenient collection of the validation data during routine testing. The matrix normalization technique and testing principles may be applicable to a wide range of analytes and biological matrices, not only those encountered in toxicology but also in other fields of bioscience. © 2023 Wiley Periodicals LLC. Basic Protocol: Detection and quantification of 102 toxicology analytes in urine by LC-ESI-MS/MS analysis using the threshold accurate calibration technique Support Protocol: Method for addition and validation of new analytes to expand the Basic Protocol.


Assuntos
Isótopos , Espectrometria de Massas em Tandem , Humanos , Espectrometria de Massas em Tandem/métodos , Cromatografia Líquida/métodos , Padrões de Referência , Toxicologia Forense/métodos
4.
Pain Med ; 23(4): 821-833, 2022 04 08.
Artigo em Inglês | MEDLINE | ID: mdl-34643732

RESUMO

OBJECTIVE: To assess routine application and clinical value of definitive urine drug monitoring (UDM) for drug detection, inconsistent drug use, and prescription adherence, along with a comparison to immunoassay screening (IAS). METHODS: Direct-to-definitive UDM performance was analyzed retrospectively in 5000 patient specimens. Drug findings, medication inconsistencies, and detection sensitivity were assessed, and definitive UDM versus IAS monitoring was studied. RESULTS: Definitive testing resulted in 18,793 drug findings with 28,403 positive drug and metabolite tests. Definitive testing expanded monitoring with 11,396 drug findings that would not be tested by IAS. The opioids accounted for the highest frequency of inconsistent positive drug-use findings, at 12%. Conversely, inconsistent negative drug findings, used as an index of prescription non-adherence, were determined in 1,751 of 15,409 monitored medications and included a high frequency of antidepressants and antipsychotics inconsistencies. Direct comparison of definitive UDM and IAS showed false-positives by IAS as well as a high rate of false-negatives that would be missed using current confirmation protocols. CONCLUSIONS: Results from routine application of direct-to-definitive UDM demonstrate the clinical value of drug-use identification and the objective evaluation of inconsistencies in drug misuse and medication adherence in pain management and addiction medicine practice. Without conversion to direct-to-definitive UDM, continuing use of IAS will limit the scope of drugs being tested, will result in an indeterminate rate of false negatives and will require confirmation testing to eliminate the reporting of false-positive IAS tests. The findings in this study provide evidence-based support for recommended use of a direct-to-definitive drug testing protocol.


Assuntos
Medicina do Vício , Transtornos Relacionados ao Uso de Substâncias , Monitoramento de Medicamentos/métodos , Humanos , Manejo da Dor , Estudos Retrospectivos , Detecção do Abuso de Substâncias/métodos , Transtornos Relacionados ao Uso de Substâncias/diagnóstico
5.
J Anal Toxicol ; 45(8): 901-912, 2021 Sep 17.
Artigo em Inglês | MEDLINE | ID: mdl-34013336

RESUMO

Analytical performance of stable isotope-labeled internal standardization (SIL-IS) and threshold accurate calibration (TAC) methods of matrix normalization are compared for quantitation of 51 drugs and metabolites (analytes) in urine with analysis by ultra performance liquid chromatography with tandem mass spectrometry (UPLC-MS-MS). Two SIL-IS methods of analysis were performed, one method using analyte-specific internal standardization (ASIL-IS) and another method using a shared stable isotope from another analyte for internal standardization (SSIL-IS). Variance in inter-specimen matrix effect, without the use of a matrix normalization method, was studied by UPLC-MS-MS analysis of 338 urine donor samples and showed >200% variation in ion response for some analytes. Matrix normalization methods were evaluated for precision, accuracy, calibration, multi-matrix recovery and positive casework quantitation. Acceptable calibration and quality control criteria were achieved for all methods when calibrators and controls were prepared from the same urine matrix pool. Quantitative accuracy, determined by the addition of analytes to multi-donor urine pools at two concentration levels, resulted in acceptable percent relative standard deviation (%RSD) and bias for TAC and ASIL-IS methods. SSIL-IS method quantitations in analyte-supplemented donor pools revealed a %RSD ranging from 20% to 60% for >30% of the analytes and a method bias that ranged up to 87%, with a differential matrix effect on analyte and shared internal standard accounting for the imprecision and bias. Analyte quantitation in 162 authentic case samples showed close agreement for TAC and ASIL-IS methods, with greater variance in the SSIL-IS method. The study demonstrates effective matrix normalization by ASIL-IS and TAC methods and a matrix-caused bias in the SSIL-IS method.


Assuntos
Preparações Farmacêuticas , Espectrometria de Massas em Tandem , Cromatografia Líquida de Alta Pressão , Cromatografia Líquida , Detecção do Abuso de Substâncias
6.
Clin Mass Spectrom ; 18: 38-47, 2020 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-34820524

RESUMO

The opioid crisis is linked to an increased misuse of fentanyl as well as fentanyl analogs that originate from the illicit drug market. Much of our current understanding of fentanyl and fentanyl analog use in our communities comes from postmortem toxicology findings. In the clinical settings of addiction medicine and pain management, where the opioid abuse potential is high, the use of fentanyl, as well as specific fentanyl analogs, may be underestimated due to limited plasma testing and limited availability of assays with suitable analytical sensitivity and selectivity to detect misuse of fentanyls. We report plasma and blood assays for 17 fentanyls (these include fentanyl, fentanyl analogs, fentanyl metabolites and synthetic precursors) in clinical, and medical examiner, casework. A mixed-mode solid phase extraction of diluted plasma or precipitated blood was optimized for maximum recovery of the fentanyls with minimized matrix effects. Analysis was performed using a Waters ACQUITY UPLC I-Class interfaced with a Waters Xevo TQ-S micro tandem quadrupole mass spectrometer. Method parameters were optimized and validated for precision, accuracy, carryover, linearity and matrix effects. Application studies were performed in postmortem blood obtained in 44 fentanyl-related fatalities and in serial plasma samples from 18 surgical patients receiving intravenous fentanyl therapy while undergoing parathyroidectomy. Fentanyls found in postmortem cases included fentanyl, norfentanyl, despropionyl-fentanyl (4-ANPP), beta-hydroxy fentanyl (ß-OH fentanyl), acetyl fentanyl, acetyl norfentanyl, methoxyacetyl fentanyl, furanyl fentanyl, cyclopropyl fentanyl, and para-fluorobutyryl fentanyl, with fentanyl, norfentanyl, 4-ANPP and ß-OH fentanyl predominating in frequency. Fentanyl concentrations ranged from 0.2 to 56 ng/mL and fentanyl was nearly always found with 4-ANPP, norfentanyl and ß-OH fentanyl. Concentrations of other fentalogs ranged from <1 to 84 ng/mL (extrapolated). In the surgical cases, fentanyl was detected and quantified along with norfentanyl and ß-OH fentanyl, but without detection of 4-ANPP in any of the samples. The association and relative concentrations of ß-OH fentanyl, fentanyl and norfentanyl in the postmortem and clinical studies indicated a metabolic, rather than an illicit, source of ß-OH fentanyl.

7.
J Anal Toxicol ; 43(5): 353-363, 2019 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-30753546

RESUMO

The transition from presumptive (immunoassay) drug screening to definitive screening has continued in the practice of analytical toxicology. Development of a ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) screening method for over sixty drugs and metabolites (analytes) in urine has been reported by the authors and has been applied in probation, drug court, social services, chemical dependency, pain management and addiction medicine casework. Testing by the definitive screening method has increased both the rate and diversity of initial-positive drug findings, due to the lower positive thresholds and wider panel of analytes. Use of definitive screening in forensic casework, however, requires retesting of initial-positive analytes using a second method based upon a different analytical technique with at least equivalent sensitivity and selectivity. Consequently, a UPLC-MSE/TOF method for confirmation of the initial-positive analytes has been adapted; the method is for targeted confirmation and is based upon an alternate mass spectrometry technology and column separation. Both the initial screen and the confirmatory analysis employ threshold accurate calibration for normalization of matrix effects, without the use of stable isotopes. Validation and application of the complete workflow, in forensic urine drug testing casework, is reported.


Assuntos
Cromatografia Líquida de Alta Pressão , Toxicologia Forense/métodos , Espectrometria de Massas , Preparações Farmacêuticas/urina , Calibragem , Toxicologia Forense/instrumentação , Humanos , Padrões de Referência , Reprodutibilidade dos Testes
8.
J Stud Alcohol Drugs ; 78(6): 945-948, 2017 11.
Artigo em Inglês | MEDLINE | ID: mdl-29087831

RESUMO

OBJECTIVE: Even moderate alcohol consumption during pregnancy can pose risks to the fetus, making reliable and consistent detection of drinking in pregnancy critical. Ethyl glucuronide (EtG) and ethyl sulfate (EtS) have shown some ability to detect lower levels of drinking, but the sensitivity of commercial EtG/EtS testing to lower levels of drinking among women of childbearing age is unknown. This study sought to determine the ability of an EtG/EtS algorithm, as well as EtG alone, to detect alcohol consumption in women of childbearing age using commercial testing and cutoffs. METHOD: Ten women (ages 21-39 years of age) were administered one, two, or three standard drinks in separate sessions. Urinary EtG/EtS was measured at baseline and again at five timed intervals for 72 hours following each session. Samples from the first five participants used a commercial algorithm in which a positive test was EtG > 100 ng/ml and EtS > 25 ng/ml; samples from the next five participants were considered positive if only EtG was >100 ng/ml. RESULTS: All samples were positive at the 12-hour follow-up. By 24 hours, sensitivity for one standard drink was poor for the combined EtG/EtS assay as well as for EtG alone (20% detection) and modest for two standard drinks (40% detection). There were no positive EtG results after 36 hours. CONCLUSIONS: The EtG/EtS cutoffs used in the present study, which are representative of those used by commercial laboratories, were not sensitive enough to reliably detect light to moderate drinking beyond a 12-hour window among women of childbearing age.


Assuntos
Consumo de Bebidas Alcoólicas/epidemiologia , Glucuronatos/urina , Detecção do Abuso de Substâncias/métodos , Ésteres do Ácido Sulfúrico/urina , Adulto , Biomarcadores , Feminino , Humanos , Gravidez , Adulto Jovem
9.
J Anal Toxicol ; 41(6): 536-546, 2017 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-28541461

RESUMO

Drug and metabolite (analytes) identification together with quantification is an important analytical tool in forensic and clinical toxicology. We report the development and validation of a definitive detection and quantification method (UPLC-MS-MS) for initial screening of 64 analytes in urine. The principle of the method is a quantitative extension of a recently reported threshold accurate calibration (TAC) technique which employs a rapid dual-specimen analysis i.e., with and without addition of a reference-analyte standard for normalization of matrix effects. Analytes include pharmaceutical and illicit agents from opiate and opioid agonist, opiate-antagonist, benzodiazepine, amphetamine, designer amphetamine, cathinone, cocaine, hallucinogen, gabapentinoid and sedative drug classes. Using a 96-well plate format, the protocol employs glucuronidase hydrolysis, 27-fold urine dilution and a 3 min UPLC-MS-MS acquisition. Subsequent data management includes calculation of a normalized TAC ratio response and weighted least squares calibration. The method utilizes analyte-specific calibration ranges from 2.5 to 1,500 ng/mL with quality control (QC) monitoring of transition-ion ratio, calibrator re-analysis, injection precision and multi-level QC analysis. Method precision, bias, calibration linearity, detection limit, carryover, crossover studies and external proficiency performance were evaluated based on pre-established criteria. The validated method provides an alternative to stable-isotope internal standardization methods of quantification and is applicable to screening with quantification in routine toxicology practice.


Assuntos
Drogas Ilícitas/urina , Detecção do Abuso de Substâncias/métodos , Calibragem , Humanos , Limite de Detecção , Controle de Qualidade , Padrões de Referência , Reprodutibilidade dos Testes
10.
J Anal Toxicol ; 40(8): 628-638, 2016 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-27562968

RESUMO

Drug screening is an essential analytical tool for detection of therapeutic, illicit and emerging drug use. Presumptive immunoassay screening is widely used, while initial definitive testing by chromatography-coupled mass spectrometry is hampered due to complex pre-analysis steps, long chromatography time and matrix effects. The aim of this study is to develop and validate a definitive test for rapid and threshold accurate screening of 33 drugs or metabolites (analytes) in urine. Sample preparation in a 96-well plate format involves rapid glucuronidase hydrolysis followed by dilution, filtration and ultra-performance liquid chromatography-MS-MS analysis. Chromatographic separation, on an ACQUITY UPLC® BEH phenyl column is optimized for a 3-min MS-MS ion acquisition. Matrix effect was normalized by an innovative technique called threshold accurate calibration employing an additional analysis with an analyte spike as an internal standard undergoing the same matrix effect as an analyte in a drug-positive donor specimen. Accuracy and precision, at above and below threshold concentrations, were determined by replicate analysis of control urine pools containing 50, 75, 125 and 150% of threshold concentrations. Accuracy and selectivity were further demonstrated by concordant findings in proficiency and confirmatory testing. The study shows the applicability of definitive testing as an alternative to immunoassay screening and demonstrates a new approach to normalization of matrix effect.


Assuntos
Cromatografia Líquida de Alta Pressão , Detecção do Abuso de Substâncias/métodos , Espectrometria de Massas em Tandem , Anfetamina/urina , Benzodiazepinas/urina , Buprenorfina/urina , Calibragem , Cocaína/urina , Humanos , Limite de Detecção , N-Metil-3,4-Metilenodioxianfetamina/urina , Alcaloides Opiáceos/urina , Oxicodona/urina , Fenciclidina/urina , Reprodutibilidade dos Testes
11.
Subst Use Misuse ; 51(1): 126-30, 2016 Jan 02.
Artigo em Inglês | MEDLINE | ID: mdl-26771303

RESUMO

BACKGROUND: Ethyl Glucoronide (EtG) and Ethyl Sulfate (EtS) have shown promise as biomarkers for alcohol and may be sensitive enough for use with pregnant women in whom even low-level alcohol use is important. However, there have been reports of over-sensitivity of EtG and EtS to incidental exposure to sources such as alcohol-based hand sanitizer. Further, few studies have evaluated these biomarkers among pregnant women, in whom the dynamics of these metabolites may differ. OBJECTIVES: This study evaluated whether commercial EtG-EtS testing was vulnerable to high levels of environmental exposure to alcohol in pregnant women. METHODS: Two separate samples of five nurses-one pregnant and the other postpartum, all of whom reported high levels of alcohol-based hand sanitizer use-provided urine samples before and 4-8 hours after rinsing with alcohol-based mouthwash and using hand sanitizer. The five pregnant nurses provided urine samples before, during, and after an 8-hour nursing shift, during which they repeatedly cleansed with alcohol-based hand sanitizer (mean 33.8 uses). The five postpartum nurses used hand sanitizer repeatedly between baseline and follow-up urine samples. RESULTS: No urine samples were positive for EtG-EtS at baseline or follow-up, despite use of mouthwash and-in the pregnant sample-heavy use of hand sanitizer (mean of 33.8 uses) throughout the 8-hour shift. CONCLUSIONS/IMPORTANCE: Current, commercially available EtG-EtS testing does not appear vulnerable to even heavy exposure to incidental sources of alcohol among pregnant and postpartum women.


Assuntos
Biomarcadores/urina , Desinfetantes/urina , Etanol/administração & dosagem , Etanol/urina , Glucuronatos , Ésteres do Ácido Sulfúrico , Adulto , Feminino , Higienizadores de Mão/química , Humanos , Antissépticos Bucais/química , Gravidez , Adulto Jovem
12.
J Anal Toxicol ; 38(8): 495-506, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25217537

RESUMO

High-resolution mass spectrometry (HRMS) is being applied in postmortem drug screening as an alternative to nominal mass spectrometry, and additional evaluation in quantitative casework is needed. We report quantitative analysis of benzoylecgonine, citalopram, cocaethylene, cocaine, codeine, dextromethorphan, dihydrocodeine, diphenhydramine, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, hydrocodone, hydromorphone, meperidine, methadone, morphine, oxycodone and oxymorphone in postmortem blood by ultra-performance liquid chromatography (UPLC)-MS(E)/time-of-flight (TOF). The method employs analyte-matched deuterated internal standardization and MS(E) acquisition of precursor and product ions at low (6 eV) and ramped (10-40 eV) collision energies, respectively. Quantification was performed using precursor ion data obtained with a mass extraction window of ± 5 ppm. Fragment and residual precursor ion acquisitions at ramped collision energies were evaluated as additional analyte identifiers. Extraction recovery of >60% and matrix effect of <20% were determined for all analytes and internal standards. Defined limits of detection (10 ng/mL) and quantification (25 ng/mL) were validated along with a linearity analytical range of 25-3,000 ng/mL (R(2) > 0.99) for all analytes. Parallel UPLC-MS(E)/TOF and UPLC-MS/MS analysis showed comparable precision and bias along with concordance of 253 positive (y = 1.002x + 1.523; R(2) = 0.993) and 2,269 negative analyte findings in 159 postmortem cases. Analytical performance and correlation studies demonstrate accurate quantification by UPLC-MS(E)/TOF and extended application of HRMS in postmortem casework.


Assuntos
Análise Química do Sangue/métodos , Cromatografia Líquida/métodos , Patologia Legal/métodos , Espectrometria de Massas em Tandem/métodos , Cromatografia Líquida de Alta Pressão/métodos , Citalopram/sangue , Cocaína/análogos & derivados , Cocaína/sangue , Codeína/análogos & derivados , Codeína/sangue , Dextrometorfano/sangue , Difenidramina/sangue , Estudos de Avaliação como Assunto , Humanos , Hidrocodona/sangue , Hidromorfona/sangue , Meperidina/sangue , Metadona/sangue , Morfina/sangue , Oxicodona/sangue , Oximorfona/sangue , Pirrolidinas/sangue , Controle de Qualidade , Reprodutibilidade dos Testes
13.
Clin Chem ; 60(1): 260-8, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24255078

RESUMO

BACKGROUND: Unconjugated estriol (uE3) is routinely analyzed in clinical laboratories as risk assessment for Down syndrome. Immunoassays of various types are the most commonly used methods. The accuracies of RIAs and ELISAs for uE3 have been questioned, and to date there have been no independent studies investigating the accuracy of the relatively new chemiluminescent immunoassays. We developed and validated a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for uE3 measurements in serum. METHODS: Serum samples from patients in the second trimester of pregnancy were used, and uE3 concentrations were measured by LC-MS/MS and the Beckman Coulter Access® 2 and Siemens IMMULITE 2000 automatic chemiluminescent immunoassay analyzers. RESULTS: The LC-MS/MS method was validated and showed limit of detection 0.05 ng/mL; limit of quantification 0.2 ng/mL; linearity of response to 32 ng/mL; total imprecision of 16.2%, 10.4%, and 8.2% for uE3 at 1.10, 4.18, and 8.32 ng/mL, respectively; and analytical recoveries of 95.9%-104.2%. ANOVA of the correlation for LC-MS/MS results vs chemiluminescent immunoassays results showed R(2) = 0.9678 (Access 2 = 0.9305 LC-MS/MS + 0.2177, Sy|x = 0.1786, P < 0.0001), and R(2) = 0.9663 (IMMULITE 2000 = 0.8849 LC-MS/MS - 0.0403, Sy|x = 0.1738, P < 0.0001). Bland-Altman plots of uE3 results revealed concentration-dependent immunoassay biases. Mock risk analysis for Down syndrome showed no apparent difference in the risk assessment outcomes if the adjusted method-specific multiples of the median were used, and the assay imprecision was <10% CV. CONCLUSIONS: Standardization of immunoassay methods for uE3 analysis is needed to improve the accuracy of the measurements.


Assuntos
Cromatografia Líquida , Testes de Química Clínica/normas , Estriol/sangue , Imunoensaio/normas , Medições Luminescentes/normas , Espectrometria de Massas em Tandem , Síndrome de Down/diagnóstico , Estriol/química , Feminino , Humanos , Masculino , Gravidez , Padrões de Referência , Reprodutibilidade dos Testes
14.
J Anal Toxicol ; 37(8): 580-93, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23999055

RESUMO

Postmortem drug findings yield important analytical evidence in medical examiner casework, and chromatography coupled with nominal mass spectrometry (MS) serves as the predominant general unknown screening approach. We report screening by ultra performance liquid chromatography (UPLC) coupled with hybrid quadrupole time-of-flight mass spectrometer (MS(E)-TOF), with comparison to previously validated nominal mass UPLC-MS and UPLC-MS-MS methods. UPLC-MS(E)-TOF screening for over 950 toxicologically relevant drugs and metabolites was performed in a full-spectrum (m/z 50-1,000) mode using an MS(E) acquisition of both molecular and fragment ion data at low (6 eV) and ramped (10-40 eV) collision energies. Mass error averaged 1.27 ppm for a large panel of reference drugs and metabolites. The limit of detection by UPLC-MS(E)-TOF ranges from 0.5 to 100 ng/mL and compares closely with UPLC-MS-MS. The influence of column recovery and matrix effect on the limit of detection was demonstrated with ion suppression by matrix components correlating closely with early and late eluting reference analytes. Drug and metabolite findings by UPLC-MS(E)-TOF were compared with UPLC-MS and UPLC-MS-MS analyses of postmortem blood in 300 medical examiner cases. Positive findings by all methods totaled 1,528, with a detection rate of 57% by UPLC-MS, 72% by UPLC-MS-MS and 80% by combined UPLC-MS and UPLC-MS-MS screening. Compared with nominal mass screening methods, UPLC-MS(E)-TOF screening resulted in a 99% detection rate and, in addition, offered the potential for the detection of nontargeted analytes via high-resolution acquisition of molecular and fragment ion data.


Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Médicos Legistas , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/sangue , Toxicologia Forense/métodos , Preparações Farmacêuticas/sangue , Espectrometria de Massas em Tandem/métodos , Adulto , Calibragem , Feminino , Toxicologia Forense/instrumentação , Humanos , Limite de Detecção , Masculino , Pessoa de Meia-Idade , Mudanças Depois da Morte , Padrões de Referência , Reprodutibilidade dos Testes
15.
J Anal Toxicol ; 35(7): 411-23, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21871149

RESUMO

In the medical examiner setting, comprehensive drug screening is an essential analytical tool in the investigation of cause and manner of death.We have validated non-targeted and targeted screening assays for drugs and metabolites using ultra-performance liquid chromatography (UPLC) interfaced with mass spectrometry (MS) in single and tandem stages. For non-targeted screening by UPLC-MS electrospray interface, in-source fragmentation was used along with MS scanning (m/z 80-650) and library search for over 700 drug and metabolite analytes. Targeted detection of over 200 analytes by UPLC-MS-MS was performed with dual transition ion monitoring. Validation studies confirmed reproducibility of both mass spectra produced by in-source fragmentation and transition ion ratios by collision-cell dissociation. Lower limit of detection by UPLC-MS (10-150 ng/mL) and UPLC-MS-MS (1-50 ng/mL) was determined for a subset of drugs and correlated with extraction recovery and matrix effect. Drug findings by UPLC-MS and UPLC- MS-MS were compared with gas chromatography-mass spectrometry (GC-MS) screening in postmortem blood from 410 medical examiner cases with 1121 positive drug findings by all methods. Accuracy, based on results of confirmation testing, was high (98-99%) across all screening assays and detection sensitivity by GC-MS (71%), UPLC-MS (73%), and UPLC-MS-MS (76%) was determined. UPLC-MS plus UPLC-MS-MS screening resulted in the highest drug detection rate (95%) and provided optimal dual-screening for the postmortem casework.


Assuntos
Cromatografia Líquida/métodos , Toxicologia Forense/métodos , Preparações Farmacêuticas/sangue , Detecção do Abuso de Substâncias/métodos , Espectrometria de Massas em Tandem/métodos , Adolescente , Adulto , Idoso , Autopsia , Criança , Pré-Escolar , Feminino , Toxicologia Forense/normas , Humanos , Lactente , Limite de Detecção , Masculino , Pessoa de Meia-Idade , Controle de Qualidade , Reprodutibilidade dos Testes , Detecção do Abuso de Substâncias/normas , Adulto Jovem
16.
Antimicrob Agents Chemother ; 55(9): 4277-82, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21670191

RESUMO

While current data indicate only free (unbound) drug is pharmacologically active and is most predictive of response, pharmacodynamic studies of vancomycin have been limited to measurement of total concentrations. The protein binding of vancomycin is thought to be approximately 50%, but considerable variability surrounds this estimate. The present study sought to determine the extent of vancomycin protein binding, to identify factors that modulate its binding, and to create and validate a prediction tool to estimate the extent of protein binding based on individual clinical factors. This single-site prospective cohort study included hospitalized adult patients treated with vancomycin and with a vancomycin serum concentration determination available. Linear regression was used to predict the free vancomycin concentration (f[vanco]) and to determine the clinical factors modulating vancomycin protein binding. Among the 50 patients in the study, the mean protein binding was 41.5%. The strongest predictor of f[vanco] was the total vancomycin concentration (total [vanco]), and this was modified by dialysis and total protein of ≥6.7 g/dl as covariates. The algebraic expression from the final prediction model was f[vanco] = 0.643 + 0.560 × total [vanco] - {0.067 × total [vanco] × D} - {0.071 × total [vanco] × TP} where D = 1 if dialysis dependent or 0 if not dialysis dependent, and TP = 1 if total protein is ≥6.7 g/dl or 0 if total protein is <6.7 g/dl. The R(2) of the final prediction model was 0.959 (P < 0.001). Validation of our model was performed in 13 patients, and the predictive performance was highly favorable (R(2) was 0.9, and bias and precision were 0.18 and 0.18, respectively). Prediction models such as ours can be utilized in future pharmacokinetics and pharmacodynamics studies evaluating the exposure-response profile and to determine the pharmacodynamic target of interest as it relates to the free concentration.


Assuntos
Vancomicina/sangue , Vancomicina/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Modelos Lineares , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Ligação Proteica , Adulto Jovem
18.
World J Emerg Med ; 1(2): 104-7, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-25214950

RESUMO

BACKGROUND: Measurement of the osmol gap (OG) is a technique that is used frequently in toxic alcohol poisonings (ethylene glycol (EG) and methanol) as a rapid means to estimate exposure, and can be performed in virtually all hospital laboratories. The value of the OG has not been previously evaluated for diethylene glycol (DEG) exposures. The primary objective of this study was to evaluate the utility of the OG in estimating DEG serum concentrations using the most common formula that is currently used for estimating methanol, ethanol, and ethylene glycol concentrations. METHODS: This was a controlled laboratory investigation using serum samples individually spiked with a known quantity of toxic alcohol compared to no toxic alcohol. Test samples were spiked with ethanol, DEG, EG, and methanol. Serum chemistries and osmolality and osmolarity were determined, and the OG was determined for each specimen. RESULTS: The percent error of estimating DEG concentrations of 26.3% was similar to the mean percent error for estimating other alcohol concentrations, 30.5%±5.6% (P>0.05, 95% confidence interval 16.7%-44.3%). CONCLUSIONS: The severity of metabolic effects associated with DEG and the need to appropriately determine rescue treatments mandate early detection of significant exposures for effective triage and patient management. Our results indicate that the percent error of the osmol gap method for estimating DEG concentration is similar to that of other toxic alcohols; this simple technique could be a valuable clinical tool, since quantitative DEG analysis is rarely available.

19.
J Anal Toxicol ; 33(8): 508-13, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19874660

RESUMO

Ethylene glycol (EG), a relatively infrequent cause of fatal intoxication, presents an analytical challenge for forensic confirmation in postmortem toxicology. We report EG and glycolic acid (GA) quantification in postmortem blood by gas chromatography coupled with ion trap mass spectrometry (GC-MS) analysis using a modification of a previously reported clinical method. The method is linear from 50 to 4000 mg/L with a limit of detection of 25 mg/L for both EG and GA. Interassay coefficient of variation (2.1-8.6%, 4.3-6.0%) and accuracy (96-101%, 92-105%) were determined for EG and GA, respectively. EG concentration by ion trap GC-MS correlated closely (R(2) = 0.995) with EG quantified by GC-flame-ionization detection. Analysis of blood from 20 autopsies with no evidence of EG exposure did not reveal detectable EG or GA. In 12 medical examiner cases with EG poisoning as cause of death, EG concentrations ranged widely from 58 to 7790 mg/L with a mean of 1830 mg/L, and the GA concentration averaged 1360 mg/L with a narrower range of 810-1770 mg/L. EG and GA levels correlate poorly (R(2) = 0.15) in postmortem blood with discordantly low EG concentrations in two cases. Birefringent oxylate crystals in renal tissue was a consistent finding. In conclusion, a sensitive and specific GC-MS method for detection and quantification of EG and GA has been validated and a study of fatal EG poisonings revealed forensic application of the method.


Assuntos
Etilenoglicol/metabolismo , Etilenoglicol/intoxicação , Glicolatos/metabolismo , Intoxicação/diagnóstico , Birrefringência , Causas de Morte , Etilenoglicol/análise , Toxicologia Forense/métodos , Cromatografia Gasosa-Espectrometria de Massas , Glicolatos/análise , Humanos , Rim/efeitos dos fármacos , Rim/patologia , Microscopia de Polarização , Oxalatos/análise , Centros de Controle de Intoxicações , Intoxicação/etiologia , Intoxicação/mortalidade , Reprodutibilidade dos Testes , Espectrometria de Massas por Ionização por Electrospray , Espectrometria de Massas em Tandem
20.
J Anal Toxicol ; 32(8): 594-600, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19007508

RESUMO

Ethyl glucuronide (EtG) is a direct ethanol biomarker and U.S. Department of Health and Human Services has advised that specificity studies at low EtG levels are needed for distinction of ethanol consumption and incidental exposure. The authors report urinary EtG excretion with ethanol abstinence, dermal exposure and oral consumption. EtG concentration by sensitive liquid chromatography-tandem mass spectrometry measurement in 39 urine specimens from adult alcohol abstainers (< 10-62 microg/L) and in urine from 13 children (< 10-80 microg/L) indicates either unrecognized ethanol exposure or endogenous ethanol metabolism. With repetitive daily dermal exposure to hand sanitizer (60% ethanol) by 9 adults, EtG concentration ranged from < 10 to 114 microg/L in 88 first-morning void specimens. EtG excretion following a 24 g ethanol drink by 4 adults revealed maximum urine EtG concentration (12,200-83,200 microg/L) at 3 to 8 h postdose and an EtG detection window up to 25-39 h, compared to an ethanol window of only 2 to 4 h. Oral ethanol use also showed an increase in the percent (molar equivalent) ethanol excreted as EtG with increasing oral ethanol doses. Human excretion studies show 1. EtG detectable at low concentration (< 100 microg/L) when ethanol use or exposures is not evident, 2. EtG concentration less than 120 microg/L in first morning specimens from adults with repeated dermal exposure to ethanol, 3. EtG levels maximally elevated within 3-8 h and above baseline for up to 39 h after a 24 g ethanol drink, and 4. a dose-dependent increase in the percentage of ethanol excreted as EtG with increasing oral ethanol use.


Assuntos
Etanol/metabolismo , Glucuronatos/urina , Pele/metabolismo , Administração Oral , Criança , Pré-Escolar , Relação Dose-Resposta a Droga , Etanol/administração & dosagem , Humanos , Lactente
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...